European Commission approves obicetrapib, a CETP inhibitor for hypercholesterolemia, offering oral dosing and 41% LDL-C reduction in Phase 3 trials.
Boots is selling a 32p pill that has been shown to reduce high cholesterol and help maintain healthy levels. According to the ...
Cholesterol: A Hidden Threat That’s Hard to Tame In France, more than one in five adults lives with high cholesterol, ...
New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as ...
New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral ...
YouTube on MSNOpinion
I tried statins - and stopped. Here's why I'm concerned.
When I tried statin therapy as part of an experiment, I quickly developed a common side effect. But what concerned me wasn’t ...
An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to ...
First-line treatment with amivantamab plus lazertinib maintains clinically meaningful and durable antitumor efficacy in ...
Long-term ADAURA data showed sustained OS benefits with osimertinib in patients with resected EGFR-mutated NSCLC.
Despite notable advancements in the acute and long-term management, coronary artery disease and myocardial infarction (MI) ...
A major change is the adoption of the PREVENT-ASCVD equations, which estimate both 10-year and 30-year cardiovascular risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results